drugset / Trial / NCT03215966

A Study to Compare the Macitentan-tadalafil Fixed Dose Combination Tablet Relative to the Concomitant Administration of the Reference Tablets of Macitentan and Tadalafil in Healthy Subjects

NCT03215966

Phase 1 Completed 38 enrolled Actelion
RandomizedCrossoverOpen-labelOther

Summary

The primary objective of this study is to demonstrate that macitentan and tadalafil administered as a fixed combination is bioequivalent to both compounds given as separate tablets given at the same doses as in the fixed combination (i.e. whether the amounts of macitentan and tadalfil which reach the blood are comparable).

Timeline

Start
2017-08-07
Primary completion
2017-09-24
Completion
2017-09-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Macitentan Other / unclassified 10 mg Oral
Subject Tadalafil Small molecule 40 mg Oral

Indications

No indication recorded.